Carregant...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2020
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/ https://ncbi.nlm.nih.gov/pubmed/33316104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|